MX2010006854A - Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. - Google Patents

Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.

Info

Publication number
MX2010006854A
MX2010006854A MX2010006854A MX2010006854A MX2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A
Authority
MX
Mexico
Prior art keywords
biomarkers
sensitivity
methods
igf1r
therapy
Prior art date
Application number
MX2010006854A
Other languages
English (en)
Inventor
Yan Wang
Yaolin Wang
Ming Liu
Cynthia Seidel-Dugan
Diane Levitan
Wei Ding
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006854A publication Critical patent/MX2010006854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invención proporciona, por ejemplo, métodos para determinar convenientemente si una condición cancerosa en un sujeto será sensible a un inhibidor de IGF1R; la invención incluye métodos de selección de paciente y métodos de tratamiento.
MX2010006854A 2007-12-18 2008-12-17 Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. MX2010006854A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1455607P 2007-12-18 2007-12-18
US1593807P 2007-12-21 2007-12-21
US2290908P 2008-01-23 2008-01-23
PCT/US2008/087240 WO2009079587A2 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy

Publications (1)

Publication Number Publication Date
MX2010006854A true MX2010006854A (es) 2010-09-09

Family

ID=40796133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006854A MX2010006854A (es) 2007-12-18 2008-12-17 Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.

Country Status (6)

Country Link
US (1) US20110091524A1 (es)
EP (1) EP2247757A2 (es)
JP (2) JP2011505873A (es)
CA (1) CA2709827A1 (es)
MX (1) MX2010006854A (es)
WO (1) WO2009079587A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952338A (zh) 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SI2310011T1 (sl) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
BRPI0916694B1 (pt) 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
EP4218760A3 (en) 2009-04-06 2023-08-16 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
EA026815B1 (ru) * 2009-11-18 2017-05-31 Хелсинн Хелткэа Са Пероральная лекарственная форма, содержащая палоносетрон и нетупитант, капсульная лекарственная форма, способ лечения тошноты и рвоты
EP2507392A4 (en) * 2009-11-30 2013-06-05 Merck Sharp & Dohme METHOD OF IDENTIFYING AND TREATING PATIENTS SENSITIVE TO ANTI-IGF-1R INHIBITION THERAPY
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
WO2014059196A2 (en) * 2012-10-10 2014-04-17 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of sma and smn deficiency
WO2014074847A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CA2922547C (en) 2013-08-28 2020-03-10 Stemcentrx, Inc. Site-specific antibody conjugation methods and compositions
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
CN110231482B (zh) * 2014-08-26 2022-07-19 学校法人庆应义塾 抗癌剂的感受性的判定标记
US20170372347A1 (en) * 2016-06-22 2017-12-28 International Business Machines Corporation Sequence-based marketing attribution model for customer journeys
WO2019030379A1 (en) * 2017-08-10 2019-02-14 The Institute Of Cancer Research: Royal Cancer Hospital MATERIALS AND METHODS OF STRATIFICATION AND TREATMENT OF CANCERS
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
CN111394462A (zh) * 2020-04-13 2020-07-10 浙江大学 一种肝癌索拉非尼耐药circRNA标志物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
EP1613658B1 (en) * 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
AU2004296376B2 (en) * 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
DE602005025685D1 (de) * 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
JP5055284B2 (ja) * 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
EP2405270B1 (en) * 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
MX2009006466A (es) * 2006-12-13 2009-06-26 Schering Corp Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
US8492328B2 (en) * 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Also Published As

Publication number Publication date
CA2709827A1 (en) 2009-06-25
EP2247757A2 (en) 2010-11-10
US20110091524A1 (en) 2011-04-21
WO2009079587A3 (en) 2009-11-12
JP2013078341A (ja) 2013-05-02
JP2011505873A (ja) 2011-03-03
WO2009079587A2 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
PH12021550758A1 (en) The use of inhibitors of bruton`s tyrosine kinase (btk)
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2008103645A8 (en) Prostate cancer and melanoma antigens
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
WO2011015602A3 (en) Lung cancer biomarkers
IN2012DN03817A (es)
TW200639404A (en) Method of assessing the effectiveness of a treatment regimen
MX339340B (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
MY155340A (en) Use of cathepsin c
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
GB2465907A (en) VHZ for diagnosis and treatment of cancer
WO2011011453A3 (en) Phenotyping tumor-infiltrating leukocytes
UA95956C2 (uk) Набір для визначення mage-а3
WO2007081777A3 (en) METHODS FOR ACCURATELY MEASURING FREE IgE IN THE PRESENCE OF AN ANTI-IgE THERAPEUTIC
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
HC Change of company name or juridical status